Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction
Kanokwan Bunsawat, Stephen M. Ratchford, Jeremy K. Alpenglow, Soung Hun Park, Catherine L. Jarrett, Josef Stehlik, Adam S. Smith, Russell S. Richardson, D. Walter Wray
Abstract
We observed an approximately twofold improvement in conduit vessel function (brachial artery FMD), increased functional capacity (6MWT distance), and a reduction in inflammation (TNF-α and IL-18) following 3 mo of sacubitril-valsartan therapy. These findings provide important new information concerning the physiological mechanisms by which this new drug class provokes favorable changes in HFrEF pathophysiology.
Topics & Concepts
ValsartanEjection fractionMedicineHeart failureCardiologySacubitrilInternal medicineSacubitril, ValsartanBrachial arteryBlood pressureHeart Failure Treatment and ManagementCardiovascular Function and Risk FactorsCardiac Imaging and Diagnostics